M-14012 Carbohydrate Antigen 15-3 (CA15-3) Quantitative Test Kit

Clinical Significance: Elevated CA15-3 levels are primarily observed in breast cancer, with a positivity rate of up to 80% in metastatic breast cancer. CA15-3 levels can also be elevated to varying degrees in liver cancer, colon cancer, pancreatic cancer, ovarian cancer, cervical cancer, and primary liver cancer. In non-malignant tumors of the breast and ovary, the positivity rate is generally below 10%.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Oncology Departments: For monitoring and managing breast cancer, especially in cases of metastatic breast cancer, by tracking CA15-3 levels.
Diagnostic Laboratories: For routine testing of serum CA15-3 levels to aid in the diagnosis and management of various malignancies, including liver, colon, pancreatic, ovarian, cervical, and primary liver cancers.
Cancer Screening Programs: For regular screening and monitoring of high-risk populations for early detection of breast and other associated cancers.
Gastroenterology and Gynecology Clinics: For differential diagnosis and monitoring of malignancies in the liver, colon, pancreas, ovary, and cervix.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive cancer management and early detection.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for cancer and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer detection and management in low-resource settings.